

Curriculum Vitae Short Template

Surname:	Sprigg
Forename:	Nikola
Current Position:	Professor of Stroke Medicine, University of Nottingham
Address:	D floor South Block, Queens Medical Centre, University of Nottingham, , Nottingham. NG7 2UH
Tel:	0115 8231778
Email:	Nikola.sprigg@nottingham.ac.uk

Qualifications:
<p>Bachelor of Medicine and Bachelor of Surgery: University of Sheffield. July 1995</p> <p>Doctor of Medicine: University of Nottingham. December 2007</p> <p>Fellow of Royal College of Physicians of London. July 2017 – Present day</p> <p>Associate Fellow of the HEA (D1) Teaching Qualification– 30 August 2019</p> <p>Good Clinical Practice December 1st 2020</p>
Posts Held:
<p>Professor of Stroke Medicine, University of Nottingham. Aug 2017 – present</p> <p>Stroke Association Clinical Associate Professor, University of Nottingham. March 2009 – July 2017</p> <p>Stroke Association Stroke Clinical Fellowship, University of Leicester. Nov 2007-2009</p>
Please detail current research projects you are working on, with details of funding:
<ul style="list-style-type: none"> • Desmopressin for treatment of patients taking Antiplatelet agents with Stroke due to Haemorrhage (DASH). Sprigg, N., Desborough, P., Bath, P.et.al. NIHR RfPB PB-PG-0816-20011 £246,777. Jun 2018. CI and Lead applicant • Tranexamic acid for hyperacute spontaneous Intracerebral Haemorrhage (TICH-3) Sprigg N, Bath P, et al. NIHR129917 HTA £4,618,606. 2021. 7.25 years. Lead applicant and Chief Investigator

Recent Publications:

- Ovesen, C., Jakobsen, J. C., Gluud, C., Steiner, T., Law, Z., Flaherty, K., ...Christensen, H. (2021). Tranexamic Acid for Prevention of Hematoma Expansion in Intracerebral Hemorrhage Patients With or Without Spot Sign. *Stroke*, 52(8), 2629-2636. <https://doi.org/10.1161/strokeaha.120.032426>
- Law, Z. K., Desborough, M., Roberts, I., Al-Shahi Salman, R., England, T. J., Werring, D. J., ...Sprigg, N. (2021). Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial. *Journal of the American Heart Association*, 10(5), <https://doi.org/10.1161/jaha.120.019130>
- Desborough MJR, Al-Shahi Salman R, Stanworth SJ, Havard D, Brennan PM, Dineen RA, Coats TJ, Hepburn T, Bath PM, **Sprigg N**. Desmopressin for reversal of Antiplatelet drugs in Stroke due to Haemorrhage (DASH): protocol for a phase II double-blind randomised controlled feasibility trial. **BMJ Open**. 2020 Nov 10;10(11):e037555. doi: 10.1136/bmjopen-2020-037555.
- Kang Law, Z., Dineen, R., England, T. J., Cala, L., Mistri, A. K., Appleton, J. P., ...TICH-2 investigators, . (2021). Predictors and outcomes of neurological deterioration in intracerebral hemorrhage: results from the TICH-2 randomised controlled trial. *Translational Stroke Research*, 12, 275-283. <https://doi.org/10.1007/s12975-020-00845-6>
- Law ZK, Ali A, Krishnan K, **Sprigg N**; TICH-2 Investigators. Noncontrast Computed Tomography Signs as Predictors of Hematoma Expansion, Clinical Outcome, and Response to Tranexamic Acid in Acute Intracerebral Hemorrhage. **Stroke**. 2020 Jan;51(1):121-128. doi: 10.1161/STROKEAHA.119.026128.
- Law, Z. K., England, T. J., Mistri, A. K., Woodhouse, L. J., Cala, L., Dineen, R., ...TICH-2 investigators, . (2020). Incidence and predictors of early seizures in intracerebral haemorrhage and the effect of tranexamic acid. *European Stroke Journal*, 5(2), 123-129. <https://doi.org/10.1177/2396987320901391>
- Hemorrhagic Stroke Academia Industry (HEADS) Roundtable Participants; Second HEADS Roundtable Participants. Recommendations for Clinical Trials in ICH: The Second Hemorrhagic Stroke Academia Industry Roundtable. **Stroke**. 2020 Apr;51(4):1333-1338. doi: 10.1161/STROKEAHA.119.027882.
- Kang Law, Z., Desborough, M., Rakkar, K., Bath, P. M., Bayraktutan, U., & Sprigg, N. (2020). Elevated plasminogen activators are associated with hematoma progression in spontaneous intracerebral hemorrhage. *Brain Hemorrhages*, 1(1), 75-79.
- **Sprigg N**, Flaherty K, et.al. Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. *Health Technol Assess*. 2019 Jul;23(35):1-48. doi: 10.3310/hta23350.